ANI, New Delhi
Published by: Surendra Joshi
Updated Wed, 09 Mar 2022 12:47 PM IST
Summary
Official sources said on Wednesday that the Hyderabad-based pharmaceutical company has submitted the vaccine data to the subject expert committee.
Biological E has sought permission for the emergency use (EUA) of Corbivax, an anti-coronavirus vaccine designed for children between the ages of 5 and 12.
Official sources said on Wednesday that the Hyderabad-based pharmaceutical company has submitted the vaccine data to the subject expert committee. Recently the subject expert committee recommended Emergency Use Authorization (EUA) for Corbivax for the age group of 12 to 18 years under certain conditions.
Official sources said on Wednesday that the Hyderabad-based pharmaceutical company has submitted the vaccine data to the subject expert committee. Recently, the subject expert committee had recommended allowing emergency use of this vaccine for the age group of 12 to 18 years under certain conditions.
It is expected that the Drug Controller General of India (DCGI) will give EUA approval to Corbivax soon. It is believed that this vaccine will cost Rs 145. It does not include tax. Its dose will be given twice after a fixed interval.
Sources told ANI that the central government has already procured 5 crore doses of Corbivax. It has also been sent to the states. Biological E applied for the second and third phase trials of this vaccine in September 2021.
India has registered 4,575 new COVID-19 cases in the last 24 hours. On Wednesday, the Ministry of Health and Family Welfare said that in the last 24 hours, more than 18.69 lakh doses of corona vaccine have been given.
Expansion
Biological E has sought permission for the emergency use (EUA) of Corbivax, an anti-coronavirus vaccine designed for children between the ages of 5 and 12.
Official sources said on Wednesday that the Hyderabad-based pharmaceutical company has submitted the vaccine data to the subject expert committee. Recently the subject expert committee recommended Emergency Use Authorization (EUA) for Corbivax for the age group of 12 to 18 years under certain conditions.
Official sources said on Wednesday that the Hyderabad-based pharmaceutical company has submitted the vaccine data to the subject expert committee. Recently, the subject expert committee had recommended allowing emergency use of this vaccine for the age group of 12 to 18 years under certain conditions.
It is expected that the Drug Controller General of India (DCGI) will give EUA approval to Corbivax soon. It is believed that this vaccine will cost Rs 145. It does not include tax. Its dose will be given twice after a fixed interval.
Sources told ANI that the central government has already procured 5 crore doses of Corbivax. It has also been sent to the states. Biological E applied for the second and third phase trials of this vaccine in September 2021.
India has registered 4,575 new COVID-19 cases in the last 24 hours. On Wednesday, the Ministry of Health and Family Welfare said that in the last 24 hours, more than 18.69 lakh doses of corona vaccine have been given.